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Abstract 
The final report of the Penrose Inquiry into historic transmission of HIV and hepatitis C 
(HCV) through blood transfusion/products in Scotland was published in March 2015 and 
recommended “everyone who had received a blood transfusion prior to 1991 and who had not 
had a test for HCV should be offered one”.  A targeted awareness-raising campaign to 
encourage such individuals to be tested was launched in October 2016. We examined HCV 
testing undertaken in 2015-16 in three NHS boards in Scotland to evaluate impact of these 
events.  Statistical process control was used to monitor trends in individuals tested and those 
mentioning transfusion.  HCV positivity was calculated and multivariate logistic regression 
was used to examine factors associated with mention of transfusion. 22,842 individuals 
received an HCV test in 2015-16 and 3% of those with clinical information mentioned 
transfusion.   For all HCV tests, the week following the Penrose Report was significantly 
higher and for tests indicating transfusion, the 3 weeks following were significantly higher.  
There was no significant increase following the awareness-raising campaign.  Women and 
those aged over 50 years were the most likely to have mentioned transfusion.  Overall HCV 
positivity was 3.7% and <1% for the transfusion group. The impact of both intense media 
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uptake was modest and short-lived.  Our findings highlight the challenges of case-finding for 
HCV and the limited impact of awareness-raising. This can be used by other countries aiming 
to identify those infected through historic blood transfusion.   
 
Introduction 
The final report of the Penrose Inquiry into the historic transmission of HIV and hepatitis C 
(HCV) through blood and blood products in Scotland was published on 25
th
 March 2015.[1]  
The report had one recommendation: everyone who received a blood transfusion prior to 
1991 and had never been tested for HCV should be offered one.  The Prime Minister of the 
United Kingdom and First Minister of Scotland apologised to the victims and their families, 
while some patient groups branded the report a “whitewash” and publicly burned 
copies.[2,3,4]  There was considerable media coverage of the report’s publication and 
subsequent response.  Much of this coverage included the recommendation that historic blood 
transfusion recipients should be tested for HCV.[5,6,7]    
The Scottish Government established a Short Life Working Group (SLWG) to consider what 
specific actions could be taken in the context of the Inquiry recommendation. This group 
estimated that 100,000 people who had received a blood transfusion prior to 1991 in Scotland 
were alive and eligible for testing under the recommendation and that only 100 of these 
(0.1%) were estimated to be HCV infected and 30 remained undiagnosed.  The SLWG 
considered various approaches to identify those eligible for testing: retrospective testing of 
blood donor specimens, interrogation of clinical records for transfusion history, notifying all 
GP patients about pre-1991 transfusion risk, delivery of a targeted awareness raising 
campaign, and general population screening.  The SLWG recognised the need to ensure that 
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these options were deemed inappropriate based on their prohibitively high costs and likely 
low effectiveness.   A targeted awareness campaign to encourage past blood transfusion 
recipients to come forward for testing was therefore recommended, with the understanding 
that the effectiveness of identifying the small number of HCV infected, undiagnosed 
individuals was uncertain and should be evaluated.[5] 
The main element of this campaign was information leaflets and posters (Appendix 1).   A 
total of 380,000 fliers and 7,500 posters were distributed with three quarters sent to 966 
general practices in Scotland and the remainder sent to a variety of settings including 
pharmacies (7%), dentists (5%), and care homes (5%).  These materials sign-posted those 
who may have had a transfusion prior to 1991 to the NHS Inform website 
(www.nhsinform.scot), a support helpline and to their general practitioner (GP).[8]  
The identification of those infected with HCV through blood transfusions prior to 1991 has 
been attempted in various countries worldwide.  The most common approach to this has been 
to undertake look-back studies using records of those known to have received a blood 
transfusion where the HCV status of the donor was either known to be positive or 
unknown.[9-14]   Blood transfusion risk has also been included in general awareness-raising 
campaigns for HCV, including those undertaken in Scotland in recent years, alongside the 
other risk groups.[15-18]  Campaigns aimed exclusively at blood transfusion recipients have 
been rare. [19]  
Here we present results of analysis of HCV test uptake following the intense media coverage 
of the Penrose Report publication in 2015 and the government funded awareness-raising 
campaign targeting this risk group in 2016 to examine the impact of these two different 
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Methods  
Data source 
Data from the Scottish Hepatitis C Test database were analysed.  The methods for this 
surveillance system have been described previously. As a sentinel surveillance system, the 
Hepatitis C Test database includes data from the four largest NHS board areas (out of 
fourteen across Scotland) and covers 75% of testing undertaken in Scotland. Key fields in 
this database include: limited patient identifiers (first initial, soundex code of surname, sex, 
date of birth; Community Health Index (CHI) number); requesting clinician information 
(address and health board); test information (specimen date and anti-HCV result); and a free-
text clinical information field.[20] 
 
Preparation of data 
Data on HCV testing undertaken in the labs that service three NHS board areas NHS Lothian, 
Grampian and Tayside (serving 35% of the Scottish population) were included in this 
analysis.  One HCV Test database participating lab in NHS Greater Glasgow and Clyde was 
excluded as no clinical details were available for interrogation. HCV test data for 2015 and 
2016 were broken down into weeks (excluding week 1 in 2015 and 52 in 2016 as these weeks 
included 2014 and 2017 data respectively) and duplicate tests were removed.  The Penrose 
Inquiry Final Report was published in week 13 of 2015 and the SG awareness campaign 
launched in week 41 of 2016, data for the periods 11 weeks prior to publication date and 10 
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Analysis was restricted to testing undertaken in general practice as patients were considered 
most likely to request a test in this setting. GPs received a Chief Medical Officer (CMO) 
letter about screening of historic blood transfusion recipients in week 13 of 2015 and week 38 
in 2016.  Individuals born after 1991, when HCV screening of transfused blood began, were 
excluded.  
The reason for testing was sourced from the clinical information field, which includes 
information provided at the time of the HCV test.  Any test with clinical details available 
and/or mention of blood transfusion and/or Penrose was flagged.  Each test record was 
categorised as (1) “clinical information available, no mention of transfusion”, (2) “clinical 
information available and mention of transfusion” or (3) “no clinical information” 
 
Statistical analysis 
Trends in HCV testing across 2015/2016 were analysed using statistical process control 
(SPC) to monitor changes in trends and large aberrations. SPC is commonly used in a variety 
of settings, including health, for quality improvement purposes by distinguishing between 
“common cause” or normal variations and “special cause” or unusual variations in trend 
data.[21]  SPC has also been used to analyse routinely collected data for research. [22] The 
SPC output includes the mean number of tests carried out per week and upper and lower 
control limits. The control limits are set at three standard deviations above and below the 
mean and so represent 99% confidence intervals. Normal variation occurs between these 
limits and any values that fall outside of these limits are significant outliers at the 1% level, 
this allows for a greater degree of “noise” in the variation and confidence that any values 
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Factors, including sex, age at time of test and the Scottish Index of Multiple Deprivation 
(SIMD), associated with mention of transfusion at the time of HCV testing were examined 
using logistic regression. Multivariate analyses were undertaken and interaction between 
factors was also considered. 
HCV antibody (anti-HCV) positivity is provided for all groups.   
 
Results 
During the study period, 22,842 individuals (11,769 in 2015 and 11,073 in 2016) received an 
HCV test.  Table 1 shows characteristics of those tested.  The majority were aged <50 years 
(60% in 2015 and 57% in 2016); the majority were in the least deprived, SIMD quintiles 3-5, 
areas (62% in 2015 and 61% in 2016) and the gender split was almost equal.   
Following interrogation of the clinical details, 78% (n=17,816) contained clinical information 
but did not mention transfusion, 3% (n=580) contained clinical information including 
transfusion (e.g. “blood transfusion as baby, worried RE: Penrose Inquiry”; “Transfusion in 
1984”), and 19% (n=4,446) did not contain any clinical information. Twenty-two tests 
mentioned “Penrose” in 2015 and no tests mentioned this risk in 2016.   
 
Testing Trends (Figure 1) 
Figure 1 shows trends in HCV testing during the study period for: all tests (figure 1a), those 
with clinical information but no mention of transfusion (figure 1b), and those with clinical 
information including transfusion (figure 1c).  For all HCV tests, one significant outlier, 
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2015, which relates to the week after publication of the Penrose report (390 tests).  One 
significant outlier, where the number of HCV tests was below the normal range, was 
identified in the clinical information and no mention of transfusion group in week 53 (96 
tests) although this was an incomplete week of data.  For HCV tests where transfusion was 
mentioned, three significant outlier weeks, where the number of HCV tests exceeded the 
normal range, were identified: in week 14 (106 tests), week 15 (76 tests) and week 16 (49 
tests).  No significant outliers were observed in relation to testing activity in the weeks 
immediately following the 2016 awareness campaign.  
Excluding the weeks following the report publication and the awareness-raising campaigns, 
where the number of tests had increased, an average of 2 HCV tests mentioning transfusion 
were expected per week (figure 1c).  In the seven weeks following the publication of the 
Penrose report, the median number of tests mentioning transfusion was 25 which represented 
a 13 fold-increase on the expected number.  In the 10 weeks following the launch of the 
awareness-raising campaign, the median number of tests mentioning transfusion was 10, 
which represents a 5 fold increase. 
 
Determinants of Blood Transfusion related testing 
Table 2 shows characteristics of all individuals tested for HCV with clinical details and those 
with mention of transfusion.  Those in the transfusion group were disproportionately female 
(82.8% compare with 49.0% of all clinical details), over 50 years old (80.5% compared with 
42.2%) and less deprived (56.7% residing in the least deprived two quintiles compared with 
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In the regression analysis, females were 3.9 times more likely to mention transfusion than 
males (P<0.001) and those over 50 years of age were 4.9 times more likely than those under 
the age of 50 (p<0.001). Compared with the most deprived SIMD quintile (SIMD 1), those 
living in quintiles 3, 4 and 5 were significantly more likely to have transfusion mentioned 
(AOR of 2.2, 2.7 and 2.6, respectively).   
 Interactions between factors were considered but none were found to be significant.  
 
HCV Positivity  
HCV positivity was 3.7% for all tests, 3.5% for those with clinical information but no 
mention of transfusion, and <1% for the transfusion group. During the study period, there 
was not significant variation in HCV positivity among the three groups (all positives, all 
positives with no mention of transfusion or positives with mention of transfusion).  
 
Discussion 
This study examined the impact on HCV testing of (1) a non-targeted media event following 
publication of the Penrose Inquiry Final Report, which included the recommendation that 
anyone who had received a blood transfusion prior to 1991 should be offered a test for HCV, 
and (2) a targeted awareness-raising campaign to address this recommendation. [1,8]   
Several days of intense media coverage were followed by a statistically significant increase in 
HCV testing in primary care.  When comparing HCV tests in 2015 and 2016, the observed 
significant increase in testing was related to tests with mention of blood transfusion/ Penrose 
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Following the launch of the awareness-raising campaign, no statistically significant increase 
in HCV testing was observed.  However, there was a modest rise in the number of tests that 
mentioned blood transfusion.  Beyond statistical significance, however, the number of 
additional tests that may be attributed to the media coverage or awareness-raising was low, 
only 580 tests mentioning blood transfusion or Penrose in 2015-16 and 448 in the weeks 
following the interventions, when compared with the estimated 35,000 people eligible (35% 
of the 100,000 estimated number of those who received a blood transfusion prior to 1991 in 
Scotland and assuming that they were equally distributed throughout the country) for testing 
under the Penrose Inquiry recommendation. [5]   While it is probable that some proportion of 
the tests without clinical details or with no mention of transfusion were among transfusion 
recipients it is unlikely to make a significant impact on the gap between the numbers reported 
here and the eligible population. Further analysis found that women aged 50 years and older 
were the most likely to have mentioned blood transfusion at the time of their test.  HCV 
positivity was found to be low, which was consistent with the estimated number of blood 
transfusion recipients thought to be positive.   
Media coverage has been widely demonstrated to increase awareness of, and screening for, 
various conditions.[23] This has the greatest impact when coverage surrounds a celebrity 
patient.[,24,25,26,27]  A study of HIV testing in Scotland found that television campaigns 
(average increase of 46%  in HIV tests over 2 months) had a greater impact on testing than 
the non-television campaigns (average increase of 6%)[28]. The short-lived increases in HIV 
testing observed in that study are consistent with the data presented here that show increases 
in HCV testing that last only seven weeks after publicity subsided. A systematic review 
examining the impact of mass-media campaigns on health behaviour found that the highest 
likelihood of success was among one-off target behaviours, such as screening, rather than 
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such campaigns was likely to be short-lived, which is consistent with our findings.[29]  
Another review of targeted HCV testing interventions found that media/information-based 
interventions were somewhat effective in increasing test uptake compared with no targeted 
testing (RR=1.26, 95% CI 0.97 to 1.64).[30]  However, these were less effective than 
practitioner-based interventions, where in-practice support was provided compared with no 
targeted testing (RR=2.24, 95% CI 1.44 to 3.48).  The most effective interventions were 
targeted at people who inject drugs (PWID). Risk-based screening among non-PWID risk 
groups poses a particular challenge.  Inability to recall past risk factors and the perception 
that they were not at risk of HCV are well established barriers to treatment related to the 
patient, particularly in an older cohort.[31,32]   
Following evidence that HCV had been transmitted through anti-D immunoglobulin in 
Ireland in 1994, a general screening programme for recipients of blood transfusions prior to 
1991 was launched.  This included considerable media coverage and communication with 
GPs and lead to almost 15,000 people, mainly women, being tested by between 1995 and 
2002, with one third of these presenting in the first four months of the programme.  While the 
combination of media coverage followed by an HCV screening programme is closest to the 
Scottish experience described here, a key difference in the Irish approach was the relatively 
short length of time (4 years) between the most recent HCV exposures and the screening 
programme, which contrasts with the interventions studied here which took place 25 years 
after the last exposures in 1991 [19] 
In 2017, a UK-wide inquiry into infected blood and blood products was announced by Prime 
Minister Theresa May. [33] The terms of reference of the Infected Blood Public Inquiry, 
chaired by Sir Brian Langstaff, cover a wide range of areas and include an aim “to ascertain 
the numbers of people infected (directly or indirectly) in consequence of the use of infected 
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been infected and might benefit from treatment...”. [34] Based on the Scottish experience, it 
is likely that there remain a proportion of transfusion recipients throughout the rest of the UK 
who have not yet been tested for HCV and there may be a similar consideration as to how to 
find them.     Our findings demonstrate that a media campaign and targeted awareness-raising 
aimed at historic transfusion recipients has had limited impact in increasing testing.  
Similarly, awareness-raising initiatives aimed at increasing HCV screening and case-finding 
among GPs has been found to have limited impact in changing testing practices in primary 
care.  [33] Surveys of GPs in Scotland undertaken in 2007 and 2013 (before and after a 
variety of government-led awareness raising initiatives) found that the offer of HCV tests was 
poor for recipients of a blood transfusion prior to 1992, with 55% of respondents in 2007 and 
46% in 2013 reporting “never/rarely” offering a test to this group.  This compared with 2% of 
GPs in both surveys reporting “never/rarely” offering current IDU an HCV test.   
In Scotland, it is estimated that approximately 15,500 individuals with chronic HCV infection 
remain undiagnosed, of whom around 30 have acquired their infection through blood 
transfusion. [34] Given the limited impact of the media coverage and awareness-raising 
campaign, identification of historic blood transfusion recipients for screening should be 
incorporated into a broader case-finding screening strategy within primary care.   There are 
several alternatives to awareness-raising, which could be utilised. Practitioner-based 
interventions have been shown to be effective in identifying former PWID in primary care. 
[29,35,36] This could be expanded to identify individuals who may have had a blood 
transfusion in the past.  A growing body of evidence has demonstrated that electronic clinical 
reminders in patient management system can increase HCV test uptake and case-finding and 
again, this could be used to flag individuals who may have had a blood transfusion. [37,38]  
While less established, opt-out testing in primary care has also been demonstrated to increase 
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Using volunteered, free-text information to categorise risk will undoubtedly miss some blood 
transfusion recipients who were tested but no mention of this was made on the request.  
Similarly, some individuals who reported a blood transfusion risk may not have received one 
before 1991.  The Short Life Working Group acknowledged that it is unclear how many of 
the uninfected blood transfusion recipients had already come forward for testing and would 
therefore not do so following these interventions, which would reduce the upper estimate for 
eligible individuals as the Inquiry recommendation states that those who had received blood 
prior to 1991 and “had never been tested for HCV” should be offered one.   As we used 
secondary surveillance data only, it has not been possible to determine whether the increase 
occurred as a result of the patients coming forward for testing, their clinicians being more 
aware of the need to offer an HCV test or a combination of both.   Similarly, this analysis 
does not take account of offers of a test that a GP might make but the patient then refuses.  
We examined data from three NHS areas, which represent one third of the Scottish 
population and so the results may not be entirely representative of the whole country. Only 
ten weeks of follow up were available for the awareness-raising campaign and there may 
have subsequently been more individuals tested as a result of this campaign. Despite these 
limitations, our data demonstrate obvious trends in HCV test uptake following these 
interventions and utilising the same method allows for a comparison of the two. 
We examined uptake of HCV testing following two key events, the media coverage of the 
Penrose Inquiry report and an awareness-raising campaign targeting these individuals.  Media 
coverage led to a statistically significant but short-lived increase in testing in this group, 
while the awareness-raising campaign resulted in more limited increases.  Given the large 
number (100,000) of those eligible to be offered an HCV test under the recommendation of 
the Penrose Inquiry, the impact of both the intense media coverage and the government 
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highlight the challenges of case-finding for HCV, particularly in less common risk groups, 
and the limited impact of awareness-raising.  Instead, measures such as educational initiatives 
targeted at professional groups, electronic reminders, opt-out testing, or practitioner-based 
support in primary care should be considered.  These findings can be used by other resource 
rich countries aiming to identify those infected through historic blood transfusion.   
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Table 1: Comparison of characteristics of individuals tested for HCV test in primary care in 3 large NHS boards in Scotland by year and following 
interventions.  
    Total number of people tested 
Total number of people tested with mention of 
"transfusion" in clinical details 




Post SG awareness 
campaign (wks 42-
51)   
Characteristic   N % N % p-value N % N % p-value 
All   11769   11073     325 100.0 123 100.0   
              
  
      
Sex Male 5933 50.4 5673 51.2   51 15.7 21 17.1   
Female 5836 49.6 5400 48.8 0.215 274 84.3 102 82.9 0.723 
              
  
      
Age Group 
(years) 
<50 7011 59.6 6343 57.3   59 18.2 20 16.3   
50+ 4758 40.4 4730 42.7 <0.001 266 81.8 103 83.7 0.639 
              
  
      
SIMD quintile 1/2 (most deprived) 4371 37.1 4256 38.4 0.043 66 20.3 31 25.2 0.262 
  3/4/5 (least deprived) 7303 62.1 6744 60.9 0.075 248 76.3 92 74.8 0.739 
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Table 2: Factors associated with the mention of blood transfusion and/or Penrose in the clinical details of an HCV test in primary care in 3 large NHS 
boards in Scotland, 2015-16. 
    
Total number of 
people tested for 
HCV during study 
period with clinical 
details 
Mention of blood 
transfusion and/or 
Penrose in clinical 
details Univariate Analysis Multivariate Analysis 1 


























Sex Male 9391 (51%) 100 (17%) ref 
 
  ref 
 
  












<50 10637 (58%) 113 (19.5%) ref 
 
  ref 
 
  










SIMD quintile 1/2 (most deprived) 6799 (37%) 122 (21%) ref 
 
  ref 
 
  
  3/4/5 (least deprived) 11482 (62%) 447 (77%) 2.2 (1.8 - 2.7) <0.001 2.0 (1.6 - 2.5) <0.001 
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Figure legends: 
Figure 1.  Trends in HCV testing per week for (a) all tests, (b) those with clinical information but no 
mention of transfusion and (c) those with clinical information including transfusion.  
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